Psychedelic Mental Health
https://pubmed.ncbi.nlm.nih.gov/41997505/ Ketamine for Depression in Serious Illness: Evidence, Safety, and Practical Approaches (2026) “Safety across serious illness studies is generally favorable, with transient dissociation, hypertension, and somnolence the most common adverse effects; serious adverse events remain rare. #Ketamine and #esketamine offer the strongest evidence among rapid-acting antidepressants and may be preferred when urgent symptom relief is needed.” #mentalhealth #psychedelics
Ketamine for Depression in Serious Illness: Evidence, Safety, and Practical Approaches - PubMed
Patients with serious illness and short prognoses often experience depression and suicidal ideation. Traditional antidepressants are limited by delayed onset, creating a need for rapidly acting therapies. In this Palliative Care Rounds, we examine the evidence for ketamine/esketamine's efficacy as a …
#psychedelics #psychedelicresearch #ketamine efficacy and safety in #palliativecare the #er and the #icu leading to less #existentialdread #pain and the possibility of #esketamine leading to a #mysticalexperience which may improve outcomes and #reducesuffering #psychedelicmentalhealth https://psychedelicmentalhealth.net/psychedelics-in-palliative-care-ready-for-primetime-making-the-case-for-ketamine-assisted-psychotherapy-horowitz-et-al-2024/
Spotlight: Psychedelics in Palliative Care, Ready for Primetime! Making the Case for Ketamine-Assisted Psychotherapy (Horowitz, et al, 2024)
"Preliminary evidence demonstrates that Ketamine-Assisted Psychotherapy (KAP) can significantly improve depression, demoralization and existential distress in seriously ill people"
https://pubmed.ncbi.nlm.nih.gov/41987516/ #ketamine for acute pain in older adults in the er (2026) #esketamine
Acute pain management in older adults presenting to the emergency department: a clinical review - PubMed
Managing acute pain in older adults is a complex challenge in emergency care, influenced by age-related physiological changes, multimorbidity and altered pharmacokinetics. Inadequate treatment contributes to frailty, delirium, functional decline and reduced quality of life, yet oligoanalgesia remain …
https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2847667 #Ketamine and #esketamine can be tested as active placebos and administered in all the ways other psychedelic medicines are. These medicines are FDA approved and have been studied for 60+ years. Compare #psychedelics in a double blind study with ketamine. Wild that this isn’t the common approach in #psychedelicresearch
https://pubmed.ncbi.nlm.nih.gov/41989186/ Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes (Patel, et al, 2026) “Subanesthetic ketamine improved specific depressive symptoms in critically ill ICU patients without significant hemodynamic instability. These findings support its potential as a rapid-acting antidepressant in the ICU, warranting further prospective trials.” #ketamine #ketaminesafety #icu #mentalhealth
Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes - PubMed
BackgroundKetamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketami …
A Systematic Review and Meta-Analysis of the Efficacy and Safety of Intranasal Esketamine for Rapid Symptom Relief in Treatment-resistant Depression (Saun, et al, 2026) https://pubmed.ncbi.nlm.nih.gov/41968732/ These findings support intranasal esketamine as a rapidly acting intervention for TRD, consistent with emerging evidence on glutamatergic modulation. #ketamine #esketamine #psychedelics #depression #spravato
A Systematic Review and Meta-Analysis of the Efficacy and Safety of Intranasal Esketamine for Rapid Symptom Relief in Treatment-resistant Depression - PubMed
Esketamine demonstrates efficacy in achieving rapid relief of depressive symptoms in TRD, but findings must be interpreted with caution, given the heterogeneity and adverse event profile. Further high-quality, long-term studies are warranted to establish sustained efficacy and safety.
https://pubmed.ncbi.nlm.nih.gov/41968009/ Serotonergic and glutamatergic mechanisms converge in ketamine's rapid responses (Fogaça, 2026) These findings suggest convergent serotonergic and glutamatergic pathways underlying ketamine's antidepressant effects. #ketamine #psychedelics #depression #serotonin
Serotonergic and glutamatergic mechanisms converge in ketamine's rapid responses - PubMed
Ketamine's rapid antidepressant actions are commonly attributed to glutamatergic mechanisms. In a recent study, Luo and colleagues have shown that ketamine inhibits the serotonin transporter and that prefrontal serotonergic signaling synergizes with NMDA receptor blockade to recruit vasoactive intes …
MindTGapJust Up the Dose?: Therapy Cults are Influencing Psychedelic Medicine Standards
#Psymposia #Neşe
Apr 13, 2026
#ketamine #redflag #therapy #cults #therapycult #maps #lycos #billionaires #techbros are #candyflipping
https://www.youtube.com/watch?v=ueaXiJYyQ3w
#Psymposia #Neşe
Apr 13, 2026
#ketamine #redflag #therapy #cults #therapycult #maps #lycos #billionaires #techbros are #candyflipping
https://www.youtube.com/watch?v=ueaXiJYyQ3w
